NEUROPATHY ACTION FOUNDATION

As filed

Subsection

03

NTEE code

G96

Classification

2000

Street

1950 OLD TUSTIN AVE

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Other organizations at this address

6 other organizations in the IRS Business Master File list the same street address. matched by us

We match the street line and ZIP code as the IRS gives them, ignoring case and outer spaces and nothing else, so "AVE" and "AVENUE" count as different streets and this list can miss some. A shared address can mean related organizations or a shared office, but it can also be a registered agent, a mail drop or a service provider holding mail for unrelated clients. It is not, by itself, evidence that two organizations are connected.

• ARIZONA UROLOGICAL SOCIETY

  EIN 27-0846916

• CALIFORNIA UROLOGICAL ASSOCIATION INC

  EIN 33-0418602

• SOCIETY OF GOVERNMENT SERVICE UROLOGISTS V A HOSPITAL-112B

  EIN 74-1873489

• UROLOGIC SOCIETY FOR TRANSPLANTATION AND RENAL SURGERY

  EIN 46-3864810

• WESTERN SECTION AMERICAN UROLOGICAL ASSOCIATION INC

  EIN 95-6051202

• WESTERN UROLOGICAL FOUNDATION

  EIN 94-2957386

Mission and programs · 2025

• In 2025 the NAF released a white paper titled, Clinical Trials for Neuropathy: Looking Ahead. The paper looks at how clinical trials are developing and why participation remains a critical part of discovering new therapies. We are proud to release Clinical Trials for Neuropathy: Looking Ahead, said Dominick Spatafora, NAF board president. This study helped us take a closer look at whats working, whats emerging, and how we can continue to move toward treating and preventing neuropathy. The report explores the categories that trials are currently underway: medication and biologics, regenerative or gene-related therapies, nerve-stimulation devices, and technology like virtual-reality programs or wearable monitors.The investigation also highlights innovation in the field, including precision medicine, AI tools, and new trial designs that may shorten the time it takes to understand whether a treatment works.Despite the promising aspects of neuropathic treatments, federal funding is a concern. While the biopharmaceutical industry invested more than $200 billion in research and development in 2024, recent federal budget cuts have reduced public funding for neuropathy research. This gap puts greater pressure on private investment and patient participation to keep new therapies moving forward.The study further outlines the importance of patient representation. Many communities especially older adults, women, and people from racial and ethnic minority groups remain underrepresented in neuropathy trials. The paper points out that the reasons are usually practical ones: transportation, lack of clear information, language differences, or simply not knowing a trial exists. Inclusivity is not just a scientific priority; it is a moral one. If we want treatments that work for everyone, then everyone needs a fair chance to participate. Breaking down barriers and expanding outreach will make future therapies stronger, safer, and more effective.The paper closes by encouraging more conversation between clinicians, caregivers, and patients. Community groups and advocates can also help by sharing trustworthy trial information and encouraging more people to ask questions. To access the full white paper, please visit www.neuropathyaction.org.Additionally, since its founding in 2006, the NAF has remained committed to providing neuropathy patients with essential resources to access individualized medications, IVIG, and other treatments through patient empowerment and strategic advocacy. To this end, in 2025 the NAF: Broadened our participation in national and state coalitions to maximize our impact. o To this end the NAF was part of eighteen various state and national coalitions in 2025. Expanded advocacy efforts beyond the states to national issues that impact patient access to medications, impact affordability, and research efforts. o To this end the NAF had over fifty engagements on various federal issues that impacted neuropathy awareness, funding, or access to treatments/medications. Continued our focus on state policy ensuring patients are protected from copay diversion programs, step therapy, prior authorizations, non-medical switching, and other harmful third party (health plan, government, PBM, etc.) practices. o To this end the NAF had over one hundred engagements in the states on various awareness, education, and access issues.

  Expenses $26,724

As filed on the 2025 return.

Officers and directors · 2025

As listed in Part VII of the 2025 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. Earlier years are each on their own filing page.

Filings

• 2025

  Revenue

  $74,132

  Expenses

  $38,177

  Contributions

  $65,106

  Grants paid

  — not reported

• 2024

  Revenue

  $73,114

  Expenses

  $34,293

  Contributions

  $64,478

  Grants paid

  — not reported

• 2023

  Revenue

  $54,886

  Expenses

  $31,603

  Contributions

  $54,621

  Grants paid

  $0

• 2022

  Revenue

  $69,500

  Expenses

  $75,326

  Contributions

  $69,458

  Grants paid

  $0

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $59,218

  Expenses

  $22,534

  Assets (EOY)

  $287,362

• 2020 · 990-EZ

  Revenue

  $116,892

  Expenses

  $83,550

  Assets (EOY)

  $250,770

• 2019 · 990-EZ

  Revenue

  $111,900

  Expenses

  $78,948

  Assets (EOY)

  $217,122

• 2018 · 990-EZ

  Revenue

  $123,323

  Expenses

  $111,997

  Assets (EOY)

  $179,561

• 2017 · 990-EZ

  Revenue

  $107,482

  Expenses

  $113,931

  Assets (EOY)

  $168,885

• 2016 · 990-EZ

  Revenue

  $103,703

  Expenses

  $126,413

  Assets (EOY)

  $175,120

• 2015 · 990-EZ

  Revenue

  $120,556

  Expenses

  $114,439

  Assets (EOY)

  $197,812

• 2014 · 990-EZ

  Revenue

  $99,760

  Expenses

  $105,449

  Assets (EOY)

  $191,695

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.

Grants received

• PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

  $16,500

  2024 · GENERAL CONTRIBUTION

• PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

  $8,000

  2023 · General Contribution

• AMERICAN ONLINE GIVING FOUNDATION INC

  $5,398

  2022 · GENERAL SUPPORT

Other IRS files